Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant cardiovascular outcomes trial in abdominal obesity
2005-002942-20Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Abdominal adiposity (ABCD) and cardiac morbidity comparing Rimonabant 20 mg once daily with Placebo (2 arms). Primary endpoints: Primary endpoint 1 and Primary endpoint 2. Planned start Nov 2005; status: withdrawn.
02
Drugs
rimonabant
03
Conditions
Abdominal adiposity (ABCD)cardiac morbidity
Beyond the preview
Go deeper on 2005-002942-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002942-20.